4//SEC Filing
Trachtenberg Eric 4
Accession 0001415889-23-009137
CIK 0001479419other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 8:00 PM ET
Size
23.8 KB
Accession
0001415889-23-009137
Insider Transaction Report
Form 4
Trachtenberg Eric
General Counsel and Secretary
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,399→ 0 totalExercise: $192.00Exp: 2030-01-01→ Common Stock (2,399 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−3,059→ 0 totalExercise: $68.50Exp: 2032-01-03→ Common Stock (3,059 underlying) - Award
Common Stock
2023-05-31+15,639→ 27,134 total - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−3,000→ 0 totalExercise: $831.00Exp: 2028-04-04→ Common Stock (3,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−2,721→ 0 totalExercise: $259.50Exp: 2029-01-01→ Common Stock (2,721 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−1,999→ 0 totalExercise: $172.50Exp: 2029-10-10→ Common Stock (1,999 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−1,813→ 0 totalExercise: $343.00Exp: 2031-01-03→ Common Stock (1,813 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-05-31−648→ 0 totalExercise: $68.50Exp: 2032-01-03→ Common Stock (648 underlying)
Footnotes (10)
- [F1]On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 12,005 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,634 RSUs that vest over three years, with 86% of such RSUs vesting on May 31, 2025 and 14% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.
- [F10]The canceled option was granted on January 3, 2022 and provided for the purchase of up to 1,620 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 432 shares had vested, options to purchase 864 shares had been forfeited and options to purchase up to 324 shares were unvested assuming maximum level of achievement (options to purchase 216 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program.
- [F2]Includes 25,315 unvested RSUs.
- [F3]The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.
- [F4]The cancelled option was granted on April 5, 2018 and provided for vesting over four years beginning on the vesting commencement date of April 2, 2018, with 25% of the shares underlying the option vested on April 2, 2019, and an additional 1/48th of the shares underlying the option vested at the end of each successive one-month period thereafter.
- [F5]The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F6]The cancelled option was granted on October 11, 2019 and provided for vesting as to 1/48th of the shares underlying the option on November 15, 2019 and as to an additional 1/48th of the shares underlying the option at the end of each successive one month period thereafter.
- [F7]The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F8]The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
- [F9]The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
Documents
Issuer
Kala Pharmaceuticals, Inc.
CIK 0001479419
Entity typeother
Related Parties
1- filerCIK 0001646300
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 8:00 PM ET
- Size
- 23.8 KB